ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 55 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $59,000 | +25.5% | 117,763 | +28.2% | 0.00% | – |
| Q3 2016 | $47,000 | +1075.0% | 91,843 | +2017.7% | 0.00% | – |
| Q2 2016 | $4,000 | -91.7% | 4,337 | -93.9% | 0.00% | – |
| Q1 2016 | $48,000 | -48.4% | 70,872 | -7.6% | 0.00% | – |
| Q4 2015 | $93,000 | -44.0% | 76,662 | +3.0% | 0.00% | – |
| Q3 2015 | $166,000 | +12.9% | 74,399 | +18.1% | 0.00% | – |
| Q2 2015 | $147,000 | +23.5% | 62,975 | +13.7% | 0.00% | – |
| Q1 2015 | $119,000 | -11.9% | 55,385 | -6.4% | 0.00% | – |
| Q4 2014 | $135,000 | -8.2% | 59,145 | +7.7% | 0.00% | – |
| Q3 2014 | $147,000 | -17.9% | 54,915 | +14.3% | 0.00% | – |
| Q2 2014 | $179,000 | -96.3% | 48,063 | -88.4% | 0.00% | -100.0% |
| Q1 2014 | $4,854,000 | +45.3% | 412,783 | +3.0% | 0.00% | 0.0% |
| Q4 2013 | $3,341,000 | -13.9% | 400,609 | -4.3% | 0.00% | 0.0% |
| Q3 2013 | $3,880,000 | +7.0% | 418,576 | +13.2% | 0.00% | 0.0% |
| Q2 2013 | $3,625,000 | – | 369,925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |